Magenta Therapeutics Announces $86.4 Million Common Inventory Expense from A number of Investors

CAMBRIDGE, Mass.–(Business enterprise WIRE)–Magenta Therapeutics, Inc. (Nasdaq: MGTA), a scientific-phase biotechnology organization developing novel medicines to bring the healing electric power of stem cell transplant to extra sufferers, introduced that it has agreed to promote around 9,600,000 shares of its prevalent inventory to specific institutional buyers in a non-public placement. Magenta anticipates aggregate gross proceeds from the supplying will be $86.4 million, right before deducting approximated supplying expenses payable by the Company, dependent on the presenting cost of $9.00 for each share. The financing syndicate features Deep Track Funds, L.P., TCG X, Terrific Point Associates, LLC, OrbiMed and Janus Henderson Investors. The closing is predicted to arise on May well 14, 2021, subject matter to customary closing conditions. Magenta intends to use the web proceeds from the presenting for standard company functions and doing work capital.

The securities are remaining sold in a private placement and have not been registered below the Securities Act of 1933, as amended, and may possibly not be made available or bought in the United States absent registration or an applicable exemption from registration requirements. The Corporation has agreed to file a resale registration assertion with the Securities and Trade Fee (the “SEC”), for functions of registering the resale of the shares of widespread stock issued or issuable in link with the giving.

Crucial Info

This push release shall not represent an supply to offer or a solicitation of an provide to acquire, nor shall there be any present or sale of these securities in any point out or other jurisdiction in which these supply, solicitation or sale would be illegal prior to the registration or qualification below the securities legal guidelines of any such state or other jurisdiction. Any supplying of the securities under the resale registration statement will only be manufactured by indicates of a prospectus.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-phase biotechnology company developing medicines to carry the curative electric power of stem mobile transplant to a lot more patients with blood cancers, genetic ailments and autoimmune health conditions. Magenta is combining management in stem mobile biology and biotherapeutics advancement with clinical and regulatory know-how, a exclusive organization product and broad networks in the stem mobile transplant community to revolutionize immune reset for additional people.

Magenta is centered in Cambridge, Mass. For additional information, please check out www.magentatx.com.

Abide by Magenta on Twitter: @magentatx.

Ahead-Searching Statements

This press launch includes ahead-searching statements that are produced pursuant to the secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995. The use of phrases these as “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” or the negative of these kinds of text or other identical expressions can be applied to discover forward-seeking statements. Any ahead-searching statements provided in this push launch, such as statements relating to the expected timing for the closing of the personal placement and the predicted use of proceeds from the non-public placement, are primarily based on management’s current expectations and beliefs and are matter to a range of dangers, uncertainties and vital variables that could cause true functions or benefits to vary materially from people expressed or implied by any ahead-wanting statements contained in this push launch, which includes, devoid of limitation, uncertainties connected to current market disorders and the completion of the personal placement on the predicted conditions, or at all. These and other risks and uncertainties are explained in additional detail in the part entitled “Risk Factors” in Magenta’s Annual Report on Type 10-K submitted on March 3, 2021, as up-to-date by its Quarterly Reports on Form 10-Q and its other filings built with the SEC from time to time. Whilst Magenta’s forward-looking statements reflect the fantastic religion judgment of its management, these statements are based only on facts and components at the moment known by Magenta. As a outcome, you are cautioned not to count on these forward-wanting statements. Any forward-wanting assertion produced in this push release speaks only as of the day on which it is built. Magenta undertakes no obligation to publicly update or revise any forward-on the lookout assertion, whether as a consequence of new information and facts, potential developments or in any other case.